Information Provided By: 
Fly News Breaks for July 31, 2019
MYO
Jul 31, 2019 | 07:02 EDT
As previously reported, Ascendiant initiated Myomo with a Buy rating and a price target of $2.00. Analyst Edward Woo said Myomo's main product, the MyoPro myoelectric upper limb orthosis, has strong product potential and he believes improving reimbursement coverage will likely be a key catalyst for the stock.
News For MYO From the Last 2 Days
There are no results for your query MYO
